# Virtual live hands-on training course for

# Clinical Trials Sponsors using the EudraVigilance system

## | COURSE DATES AND TIME

Course # 25514 01-03 October 2025 14:00-18:00 CEST

Course # 25515 08-10 December 2025 09:00-13:00 CET

## | COURSE PREREQUISITIES

Participants need an active EMA account\* for the practical exercises in the EVWEB test environment (XCOMP), are required to have a good command of the English language and be proficient in using a computer and Zoom to participate effectively in the course..

Furthermore, participants are expected to work for a clinical trial sponsor organisation and to have basic background knowledge of:

• Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use

Further information on the EudraVigilance system training can be found on the dedicated EMA EudraVigilance training page.

\*EMA account management

#### **OVERVIEW**

EudraVigilance (EV) is the EU's system for managing and analysing information on adverse reactions to medicines which have been authorised or are being studied in clinical trials in the European Economic Area (EEA) and supports the reporting and analysis of suspected adverse reactions originating from clinical trials and the post-authorisation phase of medicinal products. Following the Announcement of the EMA Management Board, the use of the ISO Individual Case Safety Report (ICSR) standard based on the ICH E2B(R3) modalities became mandatory on 30 June 2022 for all reporting to EudraVigilance. Furthermore, the use of ISO standard terminology for pharmaceutical dose forms and route of administration also became mandatory at the same time.

Following the completion of this course, participants who pass the knowledge evaluation will receive a notification from the EMA. Organisations which aim to register first user RP or to use EudraVigilance web application (EVWEB) to start the electronic reporting of ICSRs to EudraVigilance for the first time, need to provide such notification for at least one user to the EMA to be able to successfully register with the EV production environment. For more information on the registration process, please consult the <u>EMA website</u>.

### | LEARNING OBJECTIVES

At the conclusion of this training course participants will be able to:

- Apply the ISO/ICH E2B(R3) format and rules to safety reporting based on practical examples for cases (SUSARs) from interventional studies of clinical trials including initial reports as well as follow-up, amendment and nullification reports and parent-child cases.
- Understand how to use EVWEB to create, send and access ICSRs and acknowledgments
- Query, view, browse and download ICSRs

#### I TARGET AUDIENCE

This training course is intended for

- Users who have to report and analyse SUSARs originated in the context of Clinical Trials, using the ISO/ICH E2B(R3) ICSR format
- Sponsors of Clinical Trials from Web Trader sender organisations (EVWEB and EV Post)





Unless otherwise disclosed, DIA acknowledges that the statements made by trainers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA. Trainers and agenda are subject to change without notice. Recording during DIA sessions is strictly prohibited without prior written consent from DIA

# AGENDA | TIMING IN CET/CEST

DAY 1			
09:00	14:00	WELCOME AND INTRODUCTION	
		<ul> <li>SESSION 1 - Introduction to the enhanced E</li> <li>Components and Functionalities</li> <li>Registration with EudraVigilance</li> <li>Re-Routing of ICSRs to NCAs in the EEA</li> </ul>	udraVigilance System
		SESSION 2 - Key Elements of the ICSR in ISO/ ICH E2B(R3) Format	
11:00	15:30	D BREAK	
		SESSION 3 - EudraVigilance users and access rights	
		SESSION 4 - Introduction to EVWEB Version 8.0	
13:00	18:00	END OF DAY 1	
DAY 2			
09:00	14:00	<ul> <li>SESSION 5 - Creating an ICSR and sending of a safety message based on a report of a suspected unexpected serious adverse reaction (SUSAR) from an interventional clinical trial [fatal case] /Theoretical part and practical exercise</li> <li>Theoretical aspects of attachments, linked reports and parent child reports</li> <li>Follow-up Report</li> <li>Amendment Report with a copy of the laboratory results that needs to be submitted as an attachment</li> <li>Saving and Printing Options</li> </ul>	
11:00	15:30	SESSION 6  Nullification of safety reports  SESSION 7  Receiving acknowledgment messages	
13:00	18:00	END OF DAY 2	
DAY 3			
09:00	14:00	SESSION 8  ICSR Simple and Advance Queries SESSION 9	What is not covered in this Training
11:00	15.70	<ul> <li>EV Post Function</li> <li>SESSION 10</li> <li>What to do in case of system failure</li> <li>SESSION 11</li> <li>EV query support options</li> </ul>	Course: • Reporting of post-authorisation suspected adverse reactions (pharmacovigilance) • Training on Clinical Trial Information System (CTIS)
11:00	15:30	<ul> <li>KNOWLEDGE EVALUATION</li> <li>Part I - Multiple Choice Questions</li> <li>Part II - Product Report Exam Case</li> </ul>	<ul> <li>Training on pharmacovigilance business processes of your organisation</li> <li>Consulting on your organisation's business rules</li> </ul>
13:00	18:00	END OF THIS TRAINING COURSE	Training on MedDRA and XEVMPD -     the Extended EudraVigilance     Medicinal Product Dictionary

**Medicinal Product Dictionary**